Eli Lilly Files 8-K: Director Changes and Compensation Details
Ticker: LLY · Form: 8-K · Filed: 2024-09-09T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, officer-compensation, board-of-directors
Related Tickers: LLY
TL;DR
Lilly's board is shuffling, with Smith out and Ricks/Finucane in. Compensation details also filed.
AI Summary
Eli Lilly and Company (LLY) filed an 8-K on September 9, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, including David A. Ricks and Anne M. Finucane. The filing also details compensatory arrangements for certain officers and includes financial statements and exhibits related to the company's operations.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance and executive compensation disclosures, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Eli Lilly and Company (company) — Filer
- Michael J. Smith (person) — Departing Director
- David A. Ricks (person) — Newly Elected Director
- Anne M. Finucane (person) — Newly Elected Director
- 0000059478-24-000213 (filing_id) — Accession Number
FAQ
Who has departed from Eli Lilly's board of directors?
Michael J. Smith has departed from Eli Lilly's board of directors.
Who has been elected to Eli Lilly's board of directors?
David A. Ricks and Anne M. Finucane have been elected to Eli Lilly's board of directors.
What other information is included in this 8-K filing?
The filing includes details on compensatory arrangements for certain officers, as well as financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on September 9, 2024.
What is the standard industrial classification for Eli Lilly & Co?
The standard industrial classification for Eli Lilly & Co is Pharmaceutical Preparations [2834].
From the Filing
0000059478-24-000213.txt : 20240909 0000059478-24-000213.hdr.sgml : 20240909 20240909070346 ACCESSION NUMBER: 0000059478-24-000213 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240905 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240909 DATE AS OF CHANGE: 20240909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 241285773 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 8-K 1 lly-20240905.htm 8-K lly-20240905 0000059478 false 0000059478 2024-09-05 2024-09-05 0000059478 us-gaap:CommonClassAMember 2024-09-05 2024-09-05 0000059478 lly:A718NotesDueJune12025Member 2024-09-05 2024-09-05 0000059478 lly:A1.625NotesDueJune22026Member 2024-09-05 2024-09-05 0000059478 lly:A2.125NotesDueJune32030Member 2024-09-05 2024-09-05 0000059478 lly:A625Notesdue2031Member 2024-09-05 2024-09-05 0000059478 lly:A500NotesDue2033Member 2024-09-05 2024-09-05 0000059478 lly:A6.77NotesDueJanuary12036Member 2024-09-05 2024-09-05 0000059478 lly:A1625NotesDue2043Member 2024-09-05 2024-09-05 0000059478 lly:A1.700Notesdue2049Member 2024-09-05 2024-09-05 0000059478 lly:A1125NotesDue2051Member 2024-09-05 2024-09-05 0000059478 lly:A1375NotesDue2061Member 2024-09-05 2024-09-05   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2024 ELI LILLY AND COMPANY (Exact Name of Registrant as Specified in its Charter)   Indiana   001-06351   35-0470950 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)     Lilly Corporate Center Indianapolis, Indiana 46285 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 317 ) 276-2000 Not Applicable (Former Name or Former Address, if Changed Since Last Report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2.): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock (no par value) LLY New York Stock Exchange 7 1/8% Notes due 2025 LLY25 New York Stock Exchange 1.625% Notes due 2026 LLY26 New York Stock Exchange 2.125% Notes due 2030 LLY30 New York Stock Exchange 0.625% Notes due 2031 LLY31 New York Stock Exchange 0.500% Notes due 2033 LLY33 New York Stock Exchange 6.77% Notes due 2036 LLY36 New York Stock Exchange 1.625% Notes due 2043 LLY43 New York Stock Exchange 1.700% Notes due 2049 LLY49A New York Stock Exchange 1.125% Note